UK-based pharmaceutical giant GlaxoSmithKline, is banking on the popularity of its consumer healthcare brands, and wider acceptance of its medical products to drive its growth momentum, according to Vice President & GM for GSK Pharmaceutical for Malaysia and Brunei, Ramil Burden.
